Brian Betts is an Oncology physician. OpenAlex indexes 238 publications with 2,149 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
909 Fulton St SE
Minneapolis, MN 55455
Telephone
612-672-7422Provider last certified this registry record 27 Jun 2023.
Clinical trials
- In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20254 payments
- Kite Pharma, Inc.Program year20252 payments
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
53.4%Short-acting sulfonamides32.9%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsAzole Antifungal20.5%Fluconazole100%Part D<11 patientsDermatology
46.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor46.6%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2018–2023 per NIH RePORTER. The latest:
- Targeting CD83 to reduce leukemia relapse and GVHD after allogeneic hematopoietic cell transplantation
University of Minnesota
FY2023$741,625R01HL167232 - Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL
University of Minnesota
FY2020$409,210R01HL133823 - Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL
University of Minnesota
FY2019$400,586R01HL133823
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations
Biology of Blood and Marrow Transplantation
2025 - JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions
Journal of Thrombosis and Haemostasis
2023 - Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
Molecular Therapy — Oncolytics
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”